Overview

Clinical Pharmacology Study of CHF1535 pMDI 50/6 µg Versus The Free Combination In Asthmatic Children 5-11 Years Old

Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The rationale is to investigate the systemic availability of BDP/B17MP and formoterol after single oral inhalation of CHF 1535 50/6 pMDI vs the free combination of approved BDP and Formoterol pMDIs, in asthmatic children (5 to 11 years old).
Phase:
Phase 2
Details
Lead Sponsor:
Chiesi Farmaceutici S.p.A.
Treatments:
Beclomethasone
Formoterol Fumarate